Loading
Repligen Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Madaus Martin D, was filed 12 Aug 2025.
Repligen Corp: what insiders have been doing
This page follows insider dealings at Repligen Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Waltham, United States. The group dates from 1981. Between 18 October 2025 and 18 October 2026, 10 insiders published 41 filings.
There is no open-market purchase to report; the filings show 8 sales worth €4.2M by 5 insiders. The totals do not cover 1 filing with an undisclosed amount. Loeillot Olivier filed the largest sale, €1.4M, on 25 September 2026, which represents 0.015% of the company's market value.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 41 filings here. Looking back to 2021, when coverage begins, insiders filed 6 purchases and 29 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 738.3 m USD and net income at 48.9 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
223
Thresholds
n/a
Buy Volume
€784,575
6 ops. · all time
Sell Volume
€13M
29 ops. · all time
Who traded when
BuySaleOlivier Loeillot4 sales
Hunt Anthony2 sales
Dawes Karen A1 sale
James Bylund1 sale
Jason K. Garland1 sale
Madaus Martin D1 buy
+1 other insider
Since the insiders bought
- +31.7%Entry US$127.15 · Close at T+365 US$167.49
- -18.8%Entry US$144.88 · Close at T+365 US$117.61
- +7.2%Entry US$164.84 · Close at T+365 US$176.76
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Repligen Corp Strong Buy (bullish), based on 20 analysts. Average price target: US$197.95.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,338 of 26,272 companies
43.9
score / 100
Value39
Quality49
FCF yld0.8%
Earn yld0.4%
EV/EBITDA·
ROE2.0%
Gross mgn52%
Net mgn6.6%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$184.17
Analyst consensus
20 analystsStrong buy
US$145.00Target US$197.95(+7%)US$235.00
Income statement
RevenueUS$738.3M
Gross profitUS$386.2M52% margin
EBITDAUS$180.9M24% margin
Net incomeUS$48.9M5.3% margin
Valuation
PER (trailing)252.3x
PER (forward)69.0x
P/Book4.9x
Beta1.08
Balance sheet & cash
Market capUS$11.7B
Total debtUS$689.9M
Free Cash FlowUS$91.7M
Debt / Equity33%
Profitability & ownership
ROE2.0%
ROA1.4%
% insiders4.7%
% institutions105.6%
Last declaration on 8 October 2026
Declarations223 total
700 shares0Common StockSEC:0001628280-26-065462:0
4,202 shares@ US$154.960.0059% mcap4.3% of flowCommon StockSEC:0001628280-26-065238:1
1,333 shares@ US$178.750.0022% mcap1.7% of flowCommonSEC144:0001959173-26-007257
4,202 shares@ US$190.000.0073% mcap5.6% of flowCommonSEC144:0001959173-26-007273
1,248 shares@ US$181.700.0021% mcap1.7% of flowCommon StockSEC:0001628280-26-064889:0
421 shares@ US$189.680.0007% mcap22.5% of flowCommon StockSEC:0001628280-26-063714:0
4,542 shares@ US$190.000.0083% mcap6.5% of flowCommon StockSEC:0001628280-26-063572:3
8,404 shares@ US$154.960.013% mcap9.8% of flowCommon StockSEC:0001628280-26-063572:0
8,404 shares@ US$190.000.015% mcap12.1% of flowCommon StockSEC:0001628280-26-063572:1
4,542 shares@ US$155.380.0068% mcap5.3% of flowCommon StockSEC:0001628280-26-063572:2
12,946 shares@ US$190.000.024% mcap18.6% of flowCommonSEC144:0001959173-26-007110
5,426 shares@ US$141.790.0073% mcap5.8% of flowCommon StockSEC:0001628280-26-063026:0
5,426 shares@ US$180.000.0093% mcap7.3% of flowCommonSEC144:0001959173-26-007059
2,842 shares@ US$169.610.0045% mcap3.6% of flowCommon StockSEC:0001628280-26-060911:0
3,035 shares@ US$165.900.0047% mcap3.7% of flowCommonSEC144:0001959173-26-006730
5,426 shares@ US$141.790.0072% mcap5.7% of flowCommon StockSEC:0001628280-26-058417:0
5,426 shares@ US$180.000.0091% mcap7.2% of flowCommonSEC144:0001959173-26-006257
530 shares@ US$150.000.0008% mcap28.7% of flowCommonSEC144:0001959173-26-005250
733 sharesCommon StockSEC:0001193125-26-285449:0
733 shares@ US$145.000.0013% mcap38.7% of flowCommonSEC144:0001959173-26-004882
3,832 shares@ US$140.000.0065% mcap3.9% of flowCommon StockSEC:0001193125-26-169682:0
5,284 shares0Common StockSEC:0001193125-26-119047:0
24,134 shares0Common StockSEC:0001193125-26-119036:0
7,751 shares0Common StockSEC:0001193125-26-119031:0
7,751 shares0Common StockSEC:0001193125-26-119034:0
25 of 223 declarations
About Repligen Corp
Repligen Corp. (NASDAQ: RGEN) is a U.S.-listed life sciences company focused on bioprocessing technologies used in the manufacturing of biologic drugs. Headquartered in Waltham, Massachusetts, United States, the company operates as a specialized supplier of critical tools, consumables, and systems that support biopharma development and production. Repligen has a meaningful global footprint: while the majority of its manufacturing sites are in the U.S., it also maintains key sites in Europe and a growing presence in Asia. Its products are marketed globally through direct commercial teams in the United States, Europe, and Asia, as well as through selected partners and distributors. ([repligen.com](https://www.repligen.com/company/about?utm_source=openai))
Founded in 1981 by two scientists, Repligen has built its identity around innovation in bioprocessing. The company’s core mission is to help biopharmaceutical manufacturers reduce time, cost, and complexity in production while improving yield and product quality. This strategic positioning matters because the broader biologics market continues to expand, driven by the rise of biologic drugs, biosimilars, biobetters, and newer therapeutic modalities. Repligen’s business model is therefore tied to structural growth in outsourced and in-house biologics manufacturing rather than to a single end-market cycle. ([repligen.com](https://www.repligen.com/company/about?utm_source=openai))
Read moreShow less
From a business-line perspective, Repligen is organized around three main franchises: Filtration, Analytics, and Proteins. In Proteins, the company develops affinity ligands and chromatography resins used in purification workflows. In Analytics, it sells systems and devices used to monitor critical process parameters and product quality attributes during manufacturing. Its Filtration franchise rounds out the portfolio with solutions designed for purification and concentration steps in biologics production. This mix gives Repligen exposure to high-value, mission-critical stages of the biomanufacturing process and supports a differentiated competitive profile versus broader industrial suppliers. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai))
Repligen’s competitive positioning is based on proprietary products, customer intimacy, and a portfolio that has been broadened through both internal development and acquisitions. Management has emphasized innovation, commercial expansion, and operational scaling as key priorities. Recent company disclosures indicate that Repligen is targeting continued growth, with product launches across Analytics, Filtration, and Proteins, and with investments to expand its international support network. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai))
Recent milestones reinforce that strategy. In March 2025, Repligen acquired a bioprocess analytics portfolio from 908 Devices, adding products such as MAVERICK, MAVEN, REBEL, and ZipChip to strengthen its Analytics offering. In 2025 it also launched the CTech SoloVPE PLUS system. In February 2026, the company reported full-year 2025 revenue of $738 million and issued 2026 guidance calling for further growth and margin expansion. In April 2026, Repligen opened a European Training & Innovation Center in Breda, the Netherlands, underscoring its global customer-support ambitions. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2025/Repligen-Purchases-Bioprocessing-Analytics-Portfolio-from-908-Devices/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
